Syncona Shs GBP (GB:SYNC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Syncona Limited’s portfolio company, Beacon Therapeutics, has reported promising three-month interim results from its Phase II DAWN trial for the gene therapy laru-zova in treating X-linked retinitis pigmentosa (XLRP). The data indicates that the therapy is well-tolerated and shows early improvements in visual acuity, suggesting potential as a significant treatment option for this progressive eye disease. This development is a positive step forward in Beacon’s efforts to bring hope to those affected by XLRP, with further trials underway.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
